Abstract
Oral fluoropyrimidines have been available for more than 10 years. Capecitabine is well established in treating solid tumors in Europe. S-1 (Teysuno®), an oral formulation containing the 5-fluorouracil (5-FU) prodrug tegafur and the two enzyme modulators gimeracil and oteracil, has not been available in non-Asia countries until recently. In Japan, S-1 in combination with cisplatin is the recommended first-line treatment in patients with gastric cancer. In Europe, the first trials with S-1 were disappointing due to high unacceptable incidences of adverse events. Pharmacokinetic studies showed differences in Asian and Caucasian patients; therefore, a new non-Asian study program was initiated, which led to the pivotal phase 3 trial First-Line Advanced Gastric Cancer Study (FLAGS). In FLAGS, 1,053 patients with advanced gastric cancer from 24 non-Asian countries were enrolled. S-1 plus cisplatin showed no overall survival (OS) benefit when compared to 5-FU plus cisplatin. The primary endpoint superior OS was not met but better tolerability was shown. A post hoc noninferiority OS and safety analysis showed that S-1 plus cisplatin has the same efficacy as 5-FU plus cisplatin but a more favorable safety profile. This led to the approval of S-1 in combination with cisplatin in gastric cancer in Europe in 2011. This article reviews the mode of action of S-1, pivotal study results from an EU point of view, and future perspectives.
References
1.
Jemal A, Bray F, Center MM, Ferlay J, et al: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2.
Verdecchia A, Francisci S, Brenner H, et al: Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784-796.
3.
Al-Batran SE, Hartmann JT, Probst S, et al: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442.
4.
Cunningham D, Starling N, Rao S, et al: Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
5.
Sanford M: S-1 (Teysuno®): a review of its use in advanced gastric cancer in non-Asian populations. Drugs 2013;73:845-855.
6.
Kang YK, Kang WK, Shin DB, et al: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673.
7.
Moehler M, Kanzler S, Geissler M, et al: A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2010;21:71-77.
8.
Malet-Martino M, Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002;7:288-323.
9.
Nakajima T, Kinoshita T, Nashimoto A, et al: Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007;94:1468-1476.
10.
Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-221.
11.
Kobayakawa M, Kojima Y: Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther 2011;4:193-201.
12.
Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.
13.
Sasako M, Sakuramoto S, Katai H, et al: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III cancer. J Clin Oncol 2011;29:4387-4393.
14.
Yoshida K, Tsuburaya A, Kobayashi M, et al: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer (meeting abstracts). J Clin Oncol 2013;31(suppl):LBA4002.
15.
Chuah B, Goh BC, Lee SC, et al: Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 2011;102:478-483.
16.
Ajani JA, Faust J, Ikeda K, et al: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005;23:6957-6965.
17.
Ajani JA, Lee FC, Singh DA, et al: Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:663-667.
18.
Ajani JA, Rodriguez W, Bodoky G, et al: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010;28:1547-1553.
19.
Lawler A, Johnston PG: The approval of Teysuno™/S-1 by the European Medicines Agency: a potentially important advance for gastric cancer patients. Oncologist 2011;16:e1-e4.
20.
Matsubara I, Kamiya J, Imai S: Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980;30:871-879.
21.
Stein A, Voigt W, Jordan K: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010;2:51-63.
22.
Yoshisue K, Masuda H, Matsushima E, et al: Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Drug Metab Dispos 2000;28:1162-1167.
23.
Shirasaka T, Yamamitsu S, Tsuji A, et al: Conceptual change in cancer chemotherapy: from an oral fluoropyrimidine drug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Investig New Drug 2000;18:315-329.
24.
Nagashima F, Ohtsu A, Yoshida S, et al: Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 2005;8:6-11.
25.
Ajani JA, Buyse M, Lichinitser M, et al: Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer 2013;49:3616-3624.
26.
Saif MW, Rosen LS, Saito K, et al: A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. Anticancer Res 2011;31:625-632.
27.
Hirata K, Horikoshi N, Aiba K, et al: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999;5:2000-2005.
28.
Heggie GD, Sommadossi JP, Cross DS, et al: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987;47:2203-2206.
29.
Okeda R, Shibutani M, Matsuo T, et al: Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine. Acta Neuropathol 1990;81:66-73.
30.
Yamashita K, Yada H, Ariyoshi T: Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs. J Toxicol Sci 2004;29:155-166.
31.
Deboever G, Hiltrop N, Cool M, et al: Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. Clin Colorectal Cancer 2013;12:8-14.
32.
Bovelli D, Plataniotis G, Roila F, et al: Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010;21(suppl 5):v277-v282.
33.
Thyss A, Milano G, Schneider M, et al: Circulating drug levels in patients presenting cardiotoxicity to 5-FU. Eur J Cancer Clin Oncol 1988;24:1675-1676.
34.
Muneoka K, Shirai Y, Yokoyama N, et al: 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. Int J Clin Oncol 2005;10:441-443.
35.
Milano G, Etienne MC, Pierrefite V, et al: Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999;79:627-630.
36.
Yamada Y, Hamaguchi T, Goto M, et al: Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 2003;89:816-820.
37.
Campone M, Frenel JS, Lichinitser MR, et al: Phase I (phI) study evaluating the cardiac safety of oral chemotherapy S-1 in patients (pts) with advanced solid tumors (abstract 11899). Proc 104th Annu Meet Am Assoc Cancer Res 2013 Apr 6-10, Washington.
38.
Walko CM, Lindley C: Capecitabine: a review. Clin Ther 2005;27:23-44.
39.
Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 1989;7:425-432.
40.
Zhang X, Cao C, Zhang Q, et al: Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis. PLoS One 2014;9:e84230.
41.
Milano G, Etienne-Grimaldi MC, Mari M, et al: Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008;66:88-95.
42.
Shirasaka T: Development history and concept of an oral anticancer agent S-1 (TS-1w): its clinical usefulness and future vistas. Jpn J Clin Oncol 2009;39:2-15.
43.
Hoff PM, Saad ED, Ajani JA, et al: Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 2003;9:134-142.
44.
Lenz HJ, Lee FC, Haller DG, et al: Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 2007;109:33-40.
45.
Ichikawa W, Takahashi K, Nihei Z, et al: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 2004;112:967-973.
47.
Matt P, van Zwieten-Boot B, Calvo Rojas G, et al: The European Medicines Agency review of tegafur/gimeracil/oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP). Oncologist 2011;16:1451-1457.
48.
Bodoky G, Carrato A, Ravaioli A, et al: Quality of life in FLAGS trial: a randomized, phase III of Teysuno® (S-1) + cisplatin (CS) compared to 5-FU + cisplatin (CF) in untreated advanced gastric cancer (AGC) patients (abstract). Ann Oncol 2012;S9:695P.
49.
Moehler M, Mahlberg R, Heinemann V, Obermannová R, Kubala E, Melichar B, Weinmann A, Scigalla P, Tesařová M, Janda P, Hédouin-Biville F, Mansoor W: Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. Gastric Cancer 2016; Epub ahead of print..
50.
Saif MW, Syrigos K, Mehra R, et al: Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: experience of 4-years. Pak J Med Sci Q 2007;23:832-839.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
